comparemela.com

Latest Breaking News On - Takeaim lymphoma - Page 1 : comparemela.com

Curis (CRIS) Announces Initial Combination Study Data from its TakeAim Lymphoma Study

Curis (CRIS) Announces Initial Combination Study Data from its TakeAim Lymphoma Study
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

James dentzerCuris incTakeaim lymphomaChief executive officerHodgkin lymphomaComplete responseNon hodgkin lymphoma

Curis Provides Third Quarter 2023 Business Update

Curis Provides Third Quarter 2023 Business Update
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesJames dentzerRoche groupDrug administrationExchange commissionCuris incPrnewswire curis incAim leukemiaTakeaim lymphomaRecent operationalTakeaim leukemiaAim lymphomaOrphan drug designationNote regarding forward looking statementsSecurities litigation reform actOberland capital

Curis Provides Second Quarter 2023 Business Update

Removal of partial clinical hold – enrolling patients at confirmed RP2D in the TakeAim Leukemia Study Enrolling patients in the TakeAim Lymphoma Study in combination with ibrutinib Strong balance.

United statesJames dentzerExchange commissionRoche groupDrug administrationPrnewswire curis incCuris incTakeaim leukemiaTakeaim lymphoma studyRecent operationalTakeaim leukemia phaseAcute myelogenous leukemiaMyelodysplastic syndromesTakeaim lymphomaJuly registered directAim lymphoma

Analyst Holds Steady On Curis As FDA Removes Partial Clinical Hold On Leukemia Study - Curis (NASDAQ:CRIS)

Thursday, the FDA removed the partial clinical hold on Curis Inc's (NASDAQ: CRIS) TakeAim Leukemia Phase 1/2 study of emavusertib 

Curis incAim leukemia phaseAcute myelogenous leukemiaMyelodysplastic syndromesTakeaim leukemiaTakeaim lymphoma

Curis, Inc - FDA Removes Partial Clinical Hold on TakeAim Leukemia Study RP2D Established at 300 mg BID

LEXINGTON - Curis, Inc., , a biotechnology company focused on the development of emavusertib, an orally available small molecule triple target inhibitor for the treatment of hematologic.

Stephanie ascherJames dentzerCuris incClinical development of curisRoche groupDrug administrationExchange commissionTakeaim leukemia phaseAcute myelogenous leukemiaMyelodysplastic syndromesTakeaim leukemiaChief executive officerComplete responsePartial hematologic recoverySenior vice presidentClinical development

vimarsana © 2020. All Rights Reserved.